Sweden
· Delayed Price · Currency is SEK Xbrane Biopharma AB Statistics
Total Valuation
STO:XBRANE has a market cap or net worth of SEK 364.05 million. The enterprise value is 488.94 million.
| Market Cap | 364.05M |
| Enterprise Value | 488.94M |
Important Dates
The last earnings date was Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:XBRANE has 1.53 billion shares outstanding. The number of shares has increased by 1,387.44% in one year.
| Current Share Class | 1.53B |
| Shares Outstanding | 1.53B |
| Shares Change (YoY) | +1,387.44% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 21.79% |
| Owned by Institutions (%) | 11.34% |
| Float | 1.20B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 1.11 |
| PS Ratio | 1.31 |
| PB Ratio | 1.68 |
| P/TBV Ratio | 1.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.04 |
| EV / Sales | 1.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.22, with a Debt / Equity ratio of 0.69.
| Current Ratio | 1.22 |
| Quick Ratio | 0.11 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.31 |
Financial Efficiency
Return on equity (ROE) is -52.69% and return on invested capital (ROIC) is -12.92%.
| Return on Equity (ROE) | -52.69% |
| Return on Assets (ROA) | -8.02% |
| Return on Invested Capital (ROIC) | -12.92% |
| Return on Capital Employed (ROCE) | -36.13% |
| Revenue Per Employee | 4.34M |
| Profits Per Employee | -2.51M |
| Employee Count | 65 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 0.27 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.60% in the last 52 weeks. The beta is 0.83, so STO:XBRANE's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | +5.60% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.18 |
| Relative Strength Index (RSI) | 53.78 |
| Average Volume (20 Days) | 21,751,501 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, STO:XBRANE had revenue of SEK 277.89 million and -160.65 million in losses. Loss per share was -0.11.
| Revenue | 277.89M |
| Gross Profit | 224.12M |
| Operating Income | -102.39M |
| Pretax Income | -149.21M |
| Net Income | -160.65M |
| EBITDA | -93.31M |
| EBIT | -102.39M |
| Loss Per Share | -0.11 |
Balance Sheet
The company has 24.71 million in cash and 149.60 million in debt, giving a net cash position of -124.89 million or -0.08 per share.
| Cash & Cash Equivalents | 24.71M |
| Total Debt | 149.60M |
| Net Cash | -124.89M |
| Net Cash Per Share | -0.08 |
| Equity (Book Value) | 216.26M |
| Book Value Per Share | 0.14 |
| Working Capital | 90.20M |
Cash Flow
| Operating Cash Flow | -89.16M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 80.65%, with operating and profit margins of -36.84% and -57.81%.
| Gross Margin | 80.65% |
| Operating Margin | -36.84% |
| Pretax Margin | -53.69% |
| Profit Margin | -57.81% |
| EBITDA Margin | -33.58% |
| EBIT Margin | -36.84% |
| FCF Margin | n/a |
Dividends & Yields
STO:XBRANE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,387.44% |
| Shareholder Yield | n/a |
| Earnings Yield | -44.13% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
STO:XBRANE has an Altman Z-Score of -2.62. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.62 |
| Piotroski F-Score | n/a |